#USA #New York #Securities Fraud #Semler Scientific #Pomerantz LLP

Pomerantz Law Firm Launches Class Action Against Semler Scientific

In a significant move that has captured the attention of the investment community, Pomerantz Law Firm has filed a class action lawsuit against Semler Scientific, Inc. (NASDAQ: SMLR). This lawsuit arises from serious allegations concerning potential securities fraud and other unlawful practices by the company’s executives. The firm has urged investors who have incurred losses to consider joining this legal action promptly before impending deadlines.

The class action is a response to alarming reports that emerged from Semler's recent communications. In its annual report for 2024, the company disclosed that the U.S. Department of Justice (DOJ) could potentially file a complaint pertaining to claims made about its QuantaFlo device, which assesses peripheral artery disease. This announcement triggered a marked decline in Semler’s stock—plummeting by $4.03, equivalent to 9.4%, following the news on March 3, 2025. Investors, understandably shaken, have been advised to act swiftly to safeguard their interests.

Class Action Invitation
Pomerantz encourages all investors who bought Semler shares during the Class Period to reach out if they wish to be appointed as Lead Plaintiff. Interested parties can contact Danielle Peyton at [email protected] or via phone at 646-581-9980 (toll-free 888.4-POMLAW, Ext. 7980). The firm requests that inquiries made through email include relevant personal information such as mailing address, telephone number, and the quantity of shares purchased.

The seriousness of the allegations is underscored by the company's prior communications, particularly regarding its interactions with the DOJ. Back in July 2017, Semler had received a civil investigative demand, hinting at underlying issues possibly affecting the company's business practices and reputation. The situation escalated in February 2025, when it was publicly revealed that settlement discussions with the DOJ had been unsuccessful, leading to even greater concern among shareholders.

In the wake of the latest developments, the company announced on April 15, 2025, that an agreement had been reached with the DOJ regarding payment of $29.75 million to settle all related claims. However, this agreement did little to stabilize investor confidence, evident in a subsequent drop of Semler’s stock price by $3.40, or 9.88%. This instability has left investors questioning the company's leadership and its ethical decision-making processes.

Pomerantz Law Firm Background
Established under the leadership of Abraham L. Pomerantz, the firm holds a storied history in the realm of corporate and securities litigation. With a legacy spanning more than 85 years, Pomerantz is recognized for its commitment to defending the rights of shareholders and fighting against corporate misconduct. Their history of securing multimillion-dollar settlements stands as a testament to their expertise and dedication.

As investors confront these unfolding events, the Pomerantz Law Firm offers a detailed resource on their website, where individuals can download a copy of the Complaint and find further information regarding the class action. This represents not only a call to action for concerned investors but also an opportunity for justice for those affected by potential wrongdoing.

In conclusion, the class action lawsuit filed by Pomerantz against Semler Scientific is a vivid reminder of the risks associated with investing in volatile markets. As the timeline for potentially joining this class action nears its end (with the cutoff set for October 28, 2025), it is critical for investors to stay informed and take action if they believe they have a case against Semler. With the firm’s commitment to holding companies accountable, many may find a pathway to recoup their losses amidst troubled waters.